Neuro

Nu Skin Kicks Off Its Global Day of Service with Projects for Children

Retrieved on: 
Tuesday, June 14, 2022
Science, Nu Skin Enterprises, Thanksgiving Point, Lists of diseases, Angel, Food, Business Angel Network of Southeast Asia, Nature, Education, Multimedia, Skin, NUS, Neuro, Growth, Patient, Inclusivism, Technology, Health, NYSE, Community centre, Learning, Collection, Heart, Good, View, United Way, Tourism, Tutoring, Pacific Ocean

PROVO, Utah, June 14, 2022 /PRNewswire/ -- Today, Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to be a global force for good.

Key Points: 
  • PROVO, Utah, June 14, 2022 /PRNewswire/ -- Today, Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts.
  • To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to be a global force for good.
  • More than 1,000 Nu Skin employees and their families will participate in a day of service to complete 15 service projects.
  • Nu Skin Enterprises, Inc. (NYSE: NUS) is a global integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform.

Cortechs.ai Appoints New Chief Financial Officer

Retrieved on: 
Tuesday, June 14, 2022
Science, CAS, Radiology, UCSD, GE, LinkedIn, FMP, Neurodegeneration, ELP, Prostate cancer, FDA, Neuro, Growth, Oncology, Patient, Cancer, GLOBE, Michi, Management science, Diagnosis, SAN, Twitter, GE Healthcare, Audit, Prostate, BS, Management, Medical imaging, Facebook, Asia-Pacific

SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Cortechs.ai is pleased to announce the appointment of its Chief Financial Officer, Michi Sassa.

Key Points: 
  • SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Cortechs.ai is pleased to announce the appointment of its Chief Financial Officer, Michi Sassa.
  • Prior to joining Cortechs.ai, Michi served as the Chief Financial Officer for the West Region in the U.S. at GE Healthcare.
  • Michi is also a graduate of GE's world-class leadership development programs: Financial Management Program (FMP), Executive Leadership Program (ELP) and Corporate Audit Staff (CAS).
  • The Audit staff is revered and respected throughout the entire financial community, making Michi an expert in the profession.

Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

Retrieved on: 
Wednesday, June 8, 2022
Science, Other Science, Research, Oncology, General Health, Health, Clinical Trials, Other Health, MBBS, Radiation, NPV, Cohort study, Radiation therapy, Multimedia, Cardiac catheterization, Cleveland Clinic, COVID-19, Molecular imaging, Radiopharmaceutical, Brain, Cancer, Interventional radiology, CEUS, PSA, Food, Positive, Magnetic resonance imaging, NPA, Solution, PPV, MD, MRCP, GE Healthcare, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Google Images, 3D ultrasound, Prostate cancer, Physician, Magnetic resonance, Radiology, Health, Neuro, Patient, Medicine, Acquisition, Department, Nuclear medicine, MRI, Emory, 18F, PET, Man, Neoplasm, PPA, Therapy, FDA, Emory University, Neuro-Oncology (journal), The Imaging Science Journal, Clinical trial, FRCR, Recurrence, Safety, Medical imaging, EU

The safety and efficacy of 18F-fluciclovine PET imaging for the detection of recurrent brain metastases has not been established.

Key Points: 
  • The safety and efficacy of 18F-fluciclovine PET imaging for the detection of recurrent brain metastases has not been established.
  • Blue Earth Diagnostics has two clinical studies investigating the use of 18F-fluciclovine PET in the detection of recurrent brain metastases.
  • The Phase 2 PURSUE trial is designed to establish image interpretation criteria for 18F-fluciclovine PET in detecting recurrent brain metastases.
  • 18F-flucivlovine is under investigation by Blue Earth Diagnostics for potential use in adults for the detection of recurrent brain metastases in patients who have previously undergone radiation therapy.

OXFORD RECOVERY CENTER EXPANDS, DOUBLES THE SIZE OF AUTISM CENTER & ESTABLISHES "THE VILLAGE OF ORC"

Retrieved on: 
Wednesday, June 8, 2022
Cerebral palsy, Life, ABA, Social skills, Stroke, Neuro, Macular degeneration, ORC, Parkinson's disease, ADD, Speech–language pathology, Autism spectrum, ADHD, CEO, Environment, Awareness, Vietnam Friendship Village, ATM, Coffee, ARTS, Traumatic brain injury, Oxford, Growth, Weight loss, Hyperbaric medicine, Patient, Employment, Health, Multiple sclerosis, COMPASS, Quality of life, Autism, Wellness, Learning, Heart, Family, Natural environment, Hospital, Toy, Residential care, Healthcare, Tourism, Depression, Neurofeedback

BRIGHTON, Mich., June 8, 2022 /PRNewswire/ -- Oxford Recovery Center (ORC) today announced the grand opening of its innovative Autism Center expansion.  The 35,000 square foot, $12 million expansion doubles the center's size to accommodate its growing autism program.  It includes therapy rooms, employee spaces and the innovative "Village of ORC."

Key Points: 
  • BRIGHTON, Mich., June 8, 2022 /PRNewswire/ -- Oxford Recovery Center (ORC) today announced the grand opening of its innovative Autism Center expansion.
  • The 35,000 square foot, $12 million expansion doubles the center's size to accommodate its growing autism program.
  • Today's Oxford Recovery Center is the result of Dr. Peterson's continuing drive and passion to provide care.
  • Oxford offers a variety of programs that strive to create a lifestyle of wellness, improved health and quality of life.

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Retrieved on: 
Tuesday, June 7, 2022
Neurofibromatosis, HDS, PSFS Building, Conference, Toxicity, Johns Hopkins University, Inflammation, NF, Disease, Neurofibromatosis type I, AMD, Therapy, Diabetic retinopathy, NF1, Neuro, HDT, Ophthalmology, GLOBE, Neurology, Technology, COVID-19, DME, Ashvattha, Pharmaceutical industry

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.

Key Points: 
  • REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1 (NF1), at the 2022 Neurofibromatosis (NF) Conference hosted by the Childrens Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 21, 2022.
  • Poster presentation details can be found below:
    Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, ophthalmology, inflammatory diseases, and neuro-oncology.
  • The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
  • HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.

ESTN Launches World's First Player-Owned Esports Metaverse Arena Featuring Universal Player Ranking Engine

Retrieved on: 
Sunday, June 5, 2022
Metaverse, Exercise, Leadership, University Players, CEO, News, NFT, Video, Tonian, Neuro, UPR, Industry, Blockchain, Video game, Esports

Esports tournament competitor pairings will be based upon the ESTN-derived Universal Player Ranking engine (UPR score) to assure like-skilled athlete match play.

Key Points: 
  • Esports tournament competitor pairings will be based upon the ESTN-derived Universal Player Ranking engine (UPR score) to assure like-skilled athlete match play.
  • ESTN plans to allow game developers to self-publish new games to the ESTN Metaverse Arena for direct-to-developer revenue pass-through.
  • The Universal Player Ranking (UPR) is designed to become the global standard in competitive gamer skills ranking.
  • The ESTN platform tracks player performance across any platform-supported game, enabling ESTN to rate player performance across multiple games, thus standardizing ranking methodologies across the entire esports landscape.

BioAdaptives Sponsors COVID-19 Long Hauler Survey

Retrieved on: 
Thursday, June 2, 2022
Exercise, Human, Company, Research, Cognition, Nutrient, Fatigue, OTC, Risk factor, Food, Ayurveda, Animal, CEO, Security (finance), Food and Drug Administration, Timeline of the COVID-19 pandemic, U.S. Securities and Exchange Commission, Pain, CDC, Volunteering, TCM, Neuro, Memory, GLOBE, Horse, Private Securities Litigation Reform Act, Health, COVID-19, Dog, PR, Sleep, Learning, Infection, GDD, Person, Pharmaceutical industry, Dietary supplement

LAS VEGAS, NV, June 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D.

Key Points: 
  • LAS VEGAS, NV, June 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D.
  • Ongoing research, including studies of natural supplements, is searching for more effective ways to manage these Long Hauler symptoms.
  • Dr. Sutton describes the reason for her survey of Long Hauler problems.
  • I am initiating this survey to see if we can find evidence that the natural supplement formulations, PluriPain, PrimiLungs and PrimiSleep, can also help to control Long Hauler symptoms.

InvestmentPitch Media Video Discusses FSD Pharma’s Submission of an Investigational New Drug or “IND” Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder

Retrieved on: 
Wednesday, June 1, 2022
Suggestion, Entrepreneurship, US, CSE, Biotechnology, Neuro, Canadian Securities Exchange, Food, Major depressive disorder, Inflammation, Share repurchase, Neurodegeneration, News, Awareness, Investigational New Drug, IND, Budget, Sale, FDA, GLOBE, Health Canada, Risk, Review, Acquisition, Multiple sclerosis, IR, NASDAQ, Clinical trial, Honours degree, Drug development, Wall Street, Regulation of tobacco by the U.S. Food and Drug Administration, Interim, Pharmaceutical industry, Risk management, Cobourg

The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.

Key Points: 
  • The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter FSD Pharma in the search box.
  • With our elite team and solid cash position, we find ourselves in a strong position initiating the efficacy trials with FSD-201.
  • Further details on the clinical trial will be released as soon as the applications complete their review processes, and the clinical trial commences.

Cellworks Singula™ TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

Retrieved on: 
Monday, June 6, 2022
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Oncology, NGS, Cell, Research, Nominal interest rate, Progression-free survival, Personalized medicine, Survival, Harvard Medical School, Neuro, Artificial intelligence, Abstract, Baptist Health South Florida, The Cancer Genome Atlas, Baptist Health, Software, Brain, Group, IDH, Guideline, Disease, GBM, Glioblastoma, Center, GEA, Agilent Technologies, Immunology, Patient, Drug combination, Trial of the century, TRI, CBM, Dana–Farber Cancer Institute, MD, NCCN, Radiation, Sequoia Capital, PFS, MGMT, Neurology, OS, TCGA, LR, UnitedHealth Group, Pharmaceutical industry, Medical device, Medical imaging

In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.

Key Points: 
  • In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.
  • The findings from using this approach in the myCare-024-04 study suggest that biosimulating guideline GBM therapies for newly diagnosed GBM patients can positively effect clinical outcomes.
  • Cellworks Singula TRI facilitates selection of optimal personalized therapies by providing patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies.
  • This information may be used to estimate increases in OS and PFS when comparing Singula TRI recommended therapies verses standard care.

Kiyatec Announces New Clinical Evidence in High Grade Glioma Accepted for Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2022

Retrieved on: 
Thursday, June 2, 2022
Technology, Research, Other Technology, Biotechnology, Health, General Health, Other Science, Science, Oncology, Glioma, TMZ, Innovation Hub, Drug development, 3D, Doctor of Philosophy, LinkedIn, Progression-free survival, HGG, Partnership, Glioblastoma, ASCO, Breast, Neuro, Patient, Twitter, Clinical trial, MGMT, Neoplasm, Medical imaging

Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be presented at ASCO 2022.

Key Points: 
  • Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be presented at ASCO 2022.
  • As a first-time ASCO presenter and exhibitor, Kiyatec will present its Clinical Services and Drug Development Services capabilities at ASCOs first-ever Innovation Hub at kiosk #IH01.
  • The ASCO meeting will be held in Chicago June 3-7, 2022.
  • In this updated cohort of 42 patients with high grade glioma, 3D Predict Glioma prospectively predicted patient response to standard of care temozolomide (TMZ), regardless of MGMT methylation status.